Zobrazeno 1 - 10
of 248
pro vyhledávání: '"Louis P, Garrison"'
Autor:
Malaz Boustani, Erin G. Doty, Louis P. Garrison Jr, Lee J. Smolen, Timothy M. Klein, Daniel R. Murphy, Andrew W. Spargo, Mark Belger, Joseph A. Johnston
Publikováno v:
Neurology and Therapy, Vol 13, Iss 6, Pp 1641-1659 (2024)
Abstract Introduction The goal of this economic model is to estimate an economically justifiable price (EJP) for using donanemab for the treatment of early symptomatic Alzheimer’s disease (AD) in the United States based on clinical data from the ph
Externí odkaz:
https://doaj.org/article/354ca1848d6343b1a1e13ff64ed0b068
Autor:
Myrto Lee, Hugo Larose, Martin Gräbeldinger, Jon Williams, Anne-Marie Baird, Susan Brown, Johannes Bruns, Russell Clark, Javier Cortes, Giuseppe Curigliano, Andrea Ferris, Louis P. Garrison, Y.K. Gupta, Ravindran Kanesvaran, Gary Lyman, Luca Pani, Zack Pemberton-Whiteley, Tomas Salmonson, Peter Sawicki, Barry Stein, Dong-Churl Suh, Galina Velikova, Jens Grueger
Publikováno v:
Health Policy Open, Vol 6, Iss , Pp 100116- (2024)
The move toward early detection and treatment of cancer presents challenges for value assessment using traditional endpoints. Current cancer management rarely considers the full economic and societal benefits of therapies. Our study used a modified D
Externí odkaz:
https://doaj.org/article/e4d6e9cf3a8d4b7d88dee937863945b9
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 13, Iss 10 (2024)
Externí odkaz:
https://doaj.org/article/0e443eabfc8c467aa15cfb0a3f5ac51b
Autor:
Sreeram V Ramagopalan, Manuel Gomes, Isabelle Durand-Zaleski, Bill Malcolm, Jose Diaz, Grace Mitchell, Jonathan Pearson-Stuttard, Louis P Garrison Jr
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 13, Iss 9 (2024)
Externí odkaz:
https://doaj.org/article/f24885864e734f09994c94a4839754e2
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Background Contemporary debates about drug pricing feature several widely held misconceptions, including the relationship between incentives and innovation, the proportion of total healthcare spending on pharmaceuticals, and whether the econ
Externí odkaz:
https://doaj.org/article/d89ed61b4c4a4740b7bc72e53f3f236e
Autor:
Eliana Biundo, Mariia Dronova, Annie Chicoye, Richard Cookson, Nancy Devlin, T. Mark Doherty, Stephanie Garcia, Antonio J. Garcia-Ruiz, Louis P. Garrison, Terry Nolan, Maarten Postma, David Salisbury, Hiral Shah, Shazia Sheikh, Richard Smith, Mondher Toumi, Jurgen Wasem, Ekkehard Beck
Publikováno v:
Vaccines, Vol 12, Iss 7, p 773 (2024)
Following the development of a value of vaccination (VoV) framework for health technology assessment/cost-effectiveness analysis (HTA/CEA), and identification of three vaccination benefits for near-term inclusion in HTA/CEA, this final paper provides
Externí odkaz:
https://doaj.org/article/99c7755ed55a42efb7c9f29e6ffa87ea
Autor:
Philip O. Buck, Dumingu Aparna Gomes, Ekkehard Beck, Noam Kirson, Matthew Mattera, Stuart Carroll, Bernhard Ultsch, Kavisha Jayasundara, Mathieu Uhart, Louis P. Garrison, Jr.
Publikováno v:
Vaccines, Vol 12, Iss 3, p 234 (2024)
The COVID-19 pandemic’s dramatic impact has been a vivid reminder that vaccines—especially in the context of infectious respiratory viruses—provide enormous societal value, well beyond the healthcare system perspective which anchors most Health
Externí odkaz:
https://doaj.org/article/7952172987994499adfb351a5b30b4ed
Autor:
Louis P Garrison, Joseph B Babigumira, Samantha Clark, Saeed S Hamid, James K Karichu, Mindy M Cheng, Maciej B Maniecki
Publikováno v:
BMJ Open, Vol 13, Iss 5 (2023)
Objectives Pakistan has a hepatitis C virus (HCV) infection prevalence of 6%–9% and aims to achieve World Health Organisation (WHO) targets for elimination of HCV by the year 2030. We aim to evaluate the potential cost-effectiveness of a reference
Externí odkaz:
https://doaj.org/article/3f7403fa2f064023993bdbfca8dfa3f1
Autor:
Maarten J. Postma, Declan Noone, Mark H. Rozenbaum, John A. Carter, Marc F. Botteman, Elisabeth Fenwick, Louis P. Garrison
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 17, Iss 1, Pp 1-8 (2022)
Abstract Conventional cost-effectiveness analysis—i.e., assessing pharmaceuticals through a cost per quality-adjusted life year (QALY) framework—originated from a societal commitment to maximize population health given limited resources. This "ex
Externí odkaz:
https://doaj.org/article/19eaa71b6ab44aa9a3c08df0b7fd8ca7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.